TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04434326
Drug: [14]CM082 suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before administration, the solid powder for administration was placed at room temperature. 40 ml drinking water was added into the drug container to prepare the suspension for the subjects to take. After that, 200 ml drinking water was used to repeatedly rinse the drug container for many times, and the subjects continued to take the lotion. Take care not to spill the liquid out of the bottle when shaking
Study: NCT04857112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, QD (Day 1-85)
Study: NCT05716295
Drug: MDK-703
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDK-703 will be administered as specified under Arm description.
Study: NCT05716295
Drug: Checkpoint Inhibitor, Immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checkpoint inhibitor will be administered as specified under Arm description.
Study: NCT04745975
Drug: Personalized treatment guided by mini-PDX and RNA sequencing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized treatment guided by mini-PDX and RNA sequencing
Study: NCT04745975
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m2 bid po
Study: NCT04787354
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 2,000 mg/m2/day
Study: NCT05223010
Drug: Melatonin 5 MG/15 ML Oral Solution 0.2mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: will be administered 1 hour before arrival to operating room
Study: NCT05223010
Drug: Melatonin 5 MG/15 ML Oral Solution 0.4mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: will be administered 1 hour before arrival to operating room
Study: NCT05631938
Drug: cytisinicline
Normalized name: cytisinicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated oral tablets containing 3 mg cytisinicline
Study: NCT04577001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active ingredient taken orally daily for 6 months
Study: NCT05157243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two matching placebo tablets administered orally with food twice daily for 5 days
Study: NCT05427084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT05155215
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 per day for 3 days (IV)
Study: NCT05364619
Drug: Qingre Huashi Granules combined the modified dual therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingre Huashi Granules combined the modified dual therapy for 14 days
Study: NCT05909826
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg PO days 1 to 21, every 4 weeks
Study: NCT05672901
Drug: Estrace 0.01% Vaginal Cream
Normalized name: Estrace 0.01% Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrace is a prescriptive female hormone indicated in the treatment of moderate to severe symptoms of Genitourinary Syndrome of Menopause.
Study: NCT04840888
Drug: LY3484356
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06376318
Drug: anti-bodies
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Dipeptidyl peptidase 3 (DPP3), Anti-Bioactive adrenomedullin (bio-ADM)
Study: NCT04956263
Drug: YG1699
Approvals — FDA: no, EMA: no, PMDA: no
Description: YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~The proposed dosage form is a yellow, film-coated tablet for oral administration. The proposed tablet strengths for the current clinical research are 5 mg and 25 mg. The tablets are packaged in high-density polyethylene (HDPE) bottles with HDPE caps and desiccant inserters. Each HDPE bottle contains 30 tablets of drug product.~The study drug YG1699 is manufactured by Youngene Therapeutics Inc., Ltd., China.
Study: NCT00368342
Drug: Erythromycin, Azithromycin , Clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00317733
Drug: Ketoprofen in Transfersome
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04678505
Drug: MK-3402
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3402 administered as a single dose of 100 mg IV infusion on the following dosage days:~Panels A to D: Day 1 Panel E: Day 1 in Periods 1 and 2
Study: NCT06306560
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy IV
Study: NCT00691795
Drug: Clonidine or fentanyl
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.
Study: NCT05331690
Drug: Nepafenac Ophthalmic
Normalized name: nepafenac ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nepafenac (Nevanac) 3 mg/ml starter the day before surgery
Study: NCT05331690
Drug: Nepafenac Ophthalmic
Normalized name: nepafenac ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nepafenac (Nevanac) 3 mg/ml started the day after surgery
Study: NCT06250959
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HyperCVAD regimen
Study: NCT06094946
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.5 micrograms/ml
Study: NCT01512316
Drug: Lactose pill
Normalized name: lactose Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: one dose, 2hrs prior to fmri
Study: NCT06313996
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06313996
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05136053
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile solution for infusion
Study: NCT04883983
Drug: Open Label Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication will be prescribed per standard treatment for initial prescription. Pain medication request at followup will be filled with open label placebo. Pain assessment surveys will be used at 2, 6, and 12 week followups.
Study: NCT06276010
Drug: unfractionated heparin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use unfractionated heparin as an anticoagulant
Study: NCT05630534
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline is a tetracycline antibiotic routinely used in clinical practice for the treatment of bacterial infection and acne.
Study: NCT05008939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received 30% oxygen for 1 hour.
Study: NCT05721196
Drug: Treatment as Usual (TaU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group of patients will receive routine treatment, which in Nigeria means attending the outpatient clinic and taking prescribed medication.
Study: NCT05556148
Drug: Otrivine Congestion Relief
Normalized name: olivine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% Nasal Spray (Xylometazoline Hydrochloride)
Study: NCT05422690
Drug: Induction Chemotherapy Triplet Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 infused on both day 1 and day 8 of a 21-day cycle. Durvalumab 1500 mg will be given on day 1 of each cycle.
Study: NCT05422690
Drug: Consolidation Doublet Therapy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 given on days 1 and 8 of a 21-day cycle with durvalumab 1500 mg given on day 1 of each cycle for 3-5 additional cycles. For the cycle directly after Y-90, gemcitabine will be kept at a dose of 300 mg/m2 to minimize risk of toxicity.
Study: NCT06208072
Drug: Eplerenone 25 mg
Normalized name: eplerenone 25 MG
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone group will be treated with Eplerenone 25mg twice daily for a total of 8 weeks
Study: NCT05796362
Drug: Azithromycin Oleogel (Oral and Rectal)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Exploratory study of a novel oleogel dosage form of Azithromycin (Zithromax)
Study: NCT04747275
Drug: Liquid stable levothyroxine (L-T4) Tirosint-SOL
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Investigation of tolerability, palatability, and adherence of liquid levothyroxine (L-T4) for 8 weeks.
Study: NCT04747275
Drug: Oral tablet levothyroxine (L-T4)
Normalized name: levothyroxine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigation of tolerability, palatability, and adherence of maintained oral tablet levothyroxine (L-T4) for 8 weeks
Study: NCT05119413
Drug: New trio de Kligman
Normalized name: Simparica TRIO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application in addition to the same sunscreen
Study: NCT05119413
Drug: Trio Kligman
Normalized name: Simparica TRIO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application in addition to the same sunscreen
Study: NCT05878691
Drug: GRC 54276
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1a: GRC 54276 QD will be administered orally from Day 1 to Day 21 in a 21-day treatment cycle.~Part 2: GRC 54276 monotherapy therapy will commence after establishment of the MTD and/or RP2D for monotherapy arm.
Study: NCT06256328
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06256328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose, once daily
Study: NCT05045274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Reperfusion therapy: primary percutaneous coronary intervention (PPCI) after DAPT loading (aspirin 300 mg and either clopidogrel 600mg or ticagrelor 180 mg orally) in the ambulance or emergency department upon diagnosis.~2. Anti-ischemic treatment: DAPT, SC-anticoagulation, beta blockers, statin or others will be individualized according to the patient condition.~3. Anti-failure treatment: Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, mineralocorticoid receptor antagonists, other diuretics will be added in case of volume overload.
Study: NCT04643483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous~Subjects will receive placebo in a pre-specified sequence during the Treatment Periods.
Study: NCT05834062
Drug: Qsymia and lifestyle management therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qsymia will be used at 3.7g mg/23 mg for 12 weeks and then increased to 7.5 mg/46 mg for the remainder of the study. Participants will be offered lifestyle management therapy.
Study: NCT04768855
Drug: LY3540378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV or SC.
Study: NCT04768855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV or SC.
Study: NCT04768855
Drug: LY3540378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05684718
Drug: BV100 (300 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution
Study: NCT04044898
Drug: ALA 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: prepare 10% ALA solution, apply topically to the affected area for 3 hours, single dose
Study: NCT05020535
Drug: MW189
Normalized name: Methoxywarfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
Study: NCT05094804
Drug: OR2805
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG1 monoclonal antibody that binds specifically to the CD163 protein.
Study: NCT04747197
Drug: EYP-1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection
Study: NCT06422000
Drug: Probiotic Formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: probiotics sachets supplementation, in the form of lyophilized lactic acid bacteria each Aluminium stick pack contains 100 mg ( Meyer et al., 2020) Probio Tec BB12-Blend 30- IF\* (SANDOZ®.) mixed with 10 ml sterile water and given by Ryle tube once daily until discharge from the unit after clinical and laboratory improvement .
Study: NCT04996004
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m\^2 by intravenous infusion in 21-day cycles for a maximum of six cycles.
Study: NCT04300751
Drug: Opioid Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active opioid agonist or placebo, administered orally
Study: NCT05262517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT05689203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06520826
Drug: Erythropoiesis Stimulating Agent
Normalized name: Erythropoiesis stimulating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care erythropoiesis stimulating agent will be administered to maintain hemoglobin within a target range of 10-11 g/dL.
Study: NCT05181124
Drug: coadministration of JP-1366 and meloxicam
Normalized name: bupivacaine and meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: An open-label, multiple-dosing, fixed sequence, 3-period design
Study: NCT05181124
Drug: coadministration of JP-1366 and naproxen
Normalized name: naproxen and diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: An open-label, multiple-dosing, fixed sequence, 3-period design
Study: NCT05181124
Drug: single-dosing of JP-1366 in Korean and Caucasian
Approvals — FDA: no, EMA: no, PMDA: no
Description: An open-label, single-dosing, parallel design
Study: NCT05966948
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline will be intra-articular injected and given two times, on day 1st and 30th day.
Study: NCT05310032
Drug: HSG4112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral adminstration
Study: NCT05310032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral adminstration
Study: NCT06427889
Drug: Canoderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: humectant
Study: NCT06427889
Drug: Oviderm
Normalized name: Poviderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: humectant + antimicrobial
Study: NCT06427889
Drug: Decubal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-humectant
Study: NCT04356677
Drug: 50 mg/mL Virazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
Study: NCT04356677
Drug: 100 mg/mL Virazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
Study: NCT05909293
Drug: Venclexta 100 MG Oral Tablet
Normalized name: Venclexta 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: When there is a deficiency of neutrophils, G-CSF treatment may be necessary. The treatment is continued until the absolute neutrophil count (ANC) reaches either \>0.5×109/L and remains at that level for 3 consecutive days, or \>2×109/L. The purpose of G-CSF therapy in this context is to stimulate the production of neutrophils and restore their levels to a sufficient and stable range. This helps to strengthen the immune system and reduce the risk of infections associated with low neutrophil counts.~When experiencing Grade 3-4 thrombocytopenia, subcutaneous injection of IL-11 can be administered as a treatment.~When symptoms of infection occur, aggressive antimicrobial therapy and other supportive treatments should be administered.~All blood products should undergo irradiation when transfused, and all blood products must be filtered before infusion.~If gastrointestinal adverse reactions occur, antiemetic medications can be administered to alleviate symptoms.
Study: NCT05860582
Drug: [14C]GB491
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 150mg dose of GB491 containing approximately 50 uCi of \[14C\]GB491.
Study: NCT05594355
Drug: TEBOFORTAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEBOFORTAN 240 mg is administrated 1 tablet per day
Study: NCT00081055
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00081055
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05755906
Drug: BD MDI 160 μg BID (320 μg/day)
Normalized name: immunoglobulin G, human 160 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)
Study: NCT06309030
Drug: Bushen quhan zhiwang decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 100ml of Bushen quhan zhiwang decoction twice a day for 3 months.
Study: NCT06309030
Drug: Bushen quhan zhiwang decoction placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 100ml of Bushen quhan zhiwang decoction placebo twice a day for 3 months.
Study: NCT04157725
Drug: Conventional Stimulation Protocol: will receive FSH/HMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (conventional stimulation protocol) will receive FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting on the 2nd day of menses. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
Study: NCT04726085
Drug: Indomethacin 150mg
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.
Study: NCT04726085
Drug: Ibuprofen 2400mg
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be randomized to either received perioperative indomethacin or ibuprofen at the time of their emergent cerclage placement for 24 hours following surgery. Patient will be followed up through our electronic medical record system to determine gestational latency to evaluate if ibuprofen is inferior to indomethacin.
Study: NCT05618808
Drug: REGN9933
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of REGN9933 by IV infusion
Study: NCT05049057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo delivered via subcutaneous injection.
Study: NCT02974777
Drug: DAPT reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of standard dose DAPT due to low platelet reactivity
Study: NCT04680767
Drug: LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT04680767
Drug: [¹⁴C]-LY3502970
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05730218
Drug: ONL1204 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONL1204 Ophthalmic Solution at one of two doses delivered via intravitreal injection
Study: NCT05850728
Drug: TLC-ART
Normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC-ART 101 contains lopinavir, ritonavir, and tenofovir in a combination nanoparticle suspension
Study: NCT05730218
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection is performed by touching the eye surface with a syringe without a needle
Study: NCT05604287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will receive a oral dose of Placebo.
Study: NCT05487196
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl belongs to the drug classification of analgesic opioid agonists and is used as the standard of care
Study: NCT05978206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06104553
Drug: SHR-A1912; R-Chemo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1912 combined with R-Chemo: SHR-A1912 + R-Chemo (Rituximab + Chemotherapy) (Phase 1b)
Study: NCT06104553
Drug: SHR-A1912; R-Chemo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1912 combined with R-Chemo: SHR-A1912 (RP2D) + R-Chemo (Rituximab + Chemotherapy) (Phase 2)
Study: NCT05543707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × placebo to match PBI-0451(Pomotrelvir) tablets administered orally BID with food for 5 days (10 total doses)
Study: NCT05559970
Drug: Convention sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional sedation receiving analgosedation with fentanyl
Study: NCT05083312
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally disintegrating tablet
Study: NCT05248880
Drug: AGN-151586
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injection
Study: NCT05248880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injection